Liakou et al. observed that CD4+ T cells from peripheral blood and tumor tissues from anti-CTLA-4 antibody-treated bladder cancer patients show increased expression of the costimulatory molecule inducible T cell costimulator (ICOS) [37]. Here, ICOS is linked to urinary bladder cancer.